UB Paderborn / Katalog / Suche / in CDI

803 ORAL Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC)

European journal of cancer (1990), 2011, Vol.47, p.S95-S96

2011

Volltextzugriff (PDF)

1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)

European journal of cancer (1990), 2011, Vol.47, p.S176-S176

2011

Volltextzugriff (PDF)

804 ORAL Evaluation of Plasma VEGFA as a Potential Predictive Pan-tumour Biomarker for Bevacizumab

European journal of cancer (1990), 2011, Vol.47, p.S96-S96

2011

Volltextzugriff (PDF)

1414 POSTER Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab

European journal of cancer (1990), 2011, Vol.47, p.S173-S173

2011

Volltextzugriff (PDF)

1412 POSTER Genetic Markers in Relation to Bevacizumab-induced Hypertension

European journal of cancer (1990), 2011, Vol.47, p.S172-S173

2011

Volltextzugriff (PDF)

1415 POSTER Blood Plasma VEGFA Analysis in the AVAGAST Randomized Study of First-line Bevacizumab (bev) + Capecitabine/Cisplatin (cape/cis) in Patients (pts) With Advanced Gastric Cancer (AGC)

European journal of cancer (1990), 2011, Vol.47, p.S173-S174

2011

Volltextzugriff (PDF)

Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors

Annals of oncology, 2017-11, Vol.28 (11), p.2882-2887

2017

Volltextzugriff (PDF)

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib

Annals of oncology, 2017-08, Vol.28 (8), p.2021-2024

2017

Volltextzugriff (PDF)

11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study

Annals of oncology, 2020-03, Vol.31, p.S3

2020

Volltextzugriff (PDF)

221 DISCUSSION 89Zr-bevacizumab PET imaging in renal cell carcinoma patients: feasibility of tumor VEGF quantification

European journal of cancer supplements, 2010, Vol.8 (7), p.72-73

2010

Volltextzugriff (PDF)

Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC)

Annals of oncology, 2012-09, Vol.23, p.ix531-ix532

2012

Volltextzugriff (PDF)

Clinical Genotyping and Efficacy Outcomes: Exploratory Biomarker Data from the Phase II Abigail Study of 1st-Line Bevacizumab + Chemotherapy in Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC)

Annals of oncology, 2012-09, Vol.23, p.ix406

2012

Volltextzugriff (PDF)

Tumour Biomarker and Plasma Time Course Data from Abigail, A Phase II Study of 1st-Line Bevacizumab + Chemotherapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC)

Annals of oncology, 2012-09, Vol.23, p.ix405

2012

Volltextzugriff (PDF)

1657P - Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC)

Annals of oncology, 2012-09, Vol.23, p.ix531-ix532

2012

Volltextzugriff (PDF)

198P - Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV) + Chemotherapy (CT) for Ovarian Cancer (OC)

Annals of oncology, 2012-09, Vol.23, p.ix81-ix82

2012

Volltextzugriff (PDF)

Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV) + Chemotherapy (CT) for Ovarian Cancer (OC)

Annals of oncology, 2012-09, Vol.23, p.ix81-ix82

2012

Volltextzugriff (PDF)

1194P - Tissue and Serum Biomarker Results from the Phase II Innovations Study in Non-Small Cell Lung Cancer (NSCLC)

Annals of oncology, 2012-09, Vol.23, p.ix390-ix390

2012

Volltextzugriff (PDF)

Tissue and Serum Biomarker Results from the Phase II Innovations Study in Non-Small Cell Lung Cancer (NSCLC)

Annals of oncology, 2012-09, Vol.23, p.ix390

2012

Volltextzugriff (PDF)

Functional consequences of DNA mismatch repair missense mutations in murine models and their impact on cancer predisposition

Biochemical Society transactions, 2005-08, Vol.33 (Pt 4), p.689

2005

Volltextzugriff (PDF)

1[alpha],25-dihydroxyvitamin D3 enhances annexin II dependent proliferation of osteoblasts

Journal of cellular biochemistry, 2007-02, Vol.100 (3), p.679-692

2007

Volltextzugriff (PDF)

1[alpha],25‐dihydroxyvitamin D 3 enhances annexin II dependent proliferation of osteoblasts

Journal of cellular biochemistry, 2007-02, Vol.100 (3), p.679-692

2007

Volltextzugriff (PDF)

Disposition of cyromazine in plants under environmental conditions

Journal of agricultural and food chemistry, 1990-03, Vol.38 (3), p.860-864

1990

Volltextzugriff (PDF)

A simplified high-performance liquid chromatographic residue procedure for the determination of glyphosate herbicide and (aminomethyl)phosphonic acid in fruits and vegetables employing postcolumn fluorogenic labeling

Journal of agricultural and food chemistry, 1983-01, Vol.31 (1), p.69-72

1983

Volltextzugriff (PDF)

Residues of phenthoate (Cidial) and its oxon on grapefruit, lemons, oranges, their fractionated products, and soil

Journal of agricultural and food chemistry, 1983-01, Vol.31 (1), p.122-127

1983

Volltextzugriff (PDF)

Thermal Activation of Albite for the Synthesis of One-Part Mix Geopolymers

Journal of the American Ceramic Society, 2012-02, Vol.95 (2), p.565-572

2012

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

803 ORAL Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC)

1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)

804 ORAL Evaluation of Plasma VEGFA as a Potential Predictive Pan-tumour Biomarker for Bevacizumab

1414 POSTER Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab

1412 POSTER Genetic Markers in Relation to Bevacizumab-induced Hypertension

1415 POSTER Blood Plasma VEGFA Analysis in the AVAGAST Randomized Study of First-line Bevacizumab (bev) + Capecitabine/Cisplatin (cape/cis) in Patients (pts) With Advanced Gastric Cancer (AGC)

Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib

11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study

221 DISCUSSION 89Zr-bevacizumab PET imaging in renal cell carcinoma patients: feasibility of tumor VEGF quantification

Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC)

Clinical Genotyping and Efficacy Outcomes: Exploratory Biomarker Data from the Phase II Abigail Study of 1st-Line Bevacizumab + Chemotherapy in Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC)

Tumour Biomarker and Plasma Time Course Data from Abigail, A Phase II Study of 1st-Line Bevacizumab + Chemotherapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC)

1657P - Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC)

198P - Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV) + Chemotherapy (CT) for Ovarian Cancer (OC)

Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV) + Chemotherapy (CT) for Ovarian Cancer (OC)

1194P - Tissue and Serum Biomarker Results from the Phase II Innovations Study in Non-Small Cell Lung Cancer (NSCLC)

Tissue and Serum Biomarker Results from the Phase II Innovations Study in Non-Small Cell Lung Cancer (NSCLC)

Functional consequences of DNA mismatch repair missense mutations in murine models and their impact on cancer predisposition

1[alpha],25-dihydroxyvitamin D3 enhances annexin II dependent proliferation of osteoblasts

1[alpha],25‐dihydroxyvitamin D 3 enhances annexin II dependent proliferation of osteoblasts

Disposition of cyromazine in plants under environmental conditions

A simplified high-performance liquid chromatographic residue procedure for the determination of glyphosate herbicide and (aminomethyl)phosphonic acid in fruits and vegetables employing postcolumn fluorogenic labeling

Residues of phenthoate (Cidial) and its oxon on grapefruit, lemons, oranges, their fractionated products, and soil

Thermal Activation of Albite for the Synthesis of One-Part Mix Geopolymers

Aktive Filter

Suchergebnisse filtern